000144571 001__ 144571
000144571 005__ 20240229123019.0
000144571 0247_ $$2doi$$a10.1080/10428194.2019.1646905
000144571 0247_ $$2pmid$$apmid:31423866
000144571 0247_ $$2ISSN$$a1026-8022
000144571 0247_ $$2ISSN$$a1029-2403
000144571 0247_ $$2ISSN$$a1042-8194
000144571 0247_ $$2altmetric$$aaltmetric:65200081
000144571 037__ $$aDKFZ-2019-02014
000144571 041__ $$aeng
000144571 082__ $$a610
000144571 1001_ $$aBlocka, Joanna$$b0
000144571 245__ $$aSalvage therapy versus upfront autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy.
000144571 260__ $$aLondon [u.a.]$$bTaylor & Francis Group$$c2020
000144571 3367_ $$2DRIVER$$aarticle
000144571 3367_ $$2DataCite$$aOutput Types/Journal article
000144571 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1578475481_25709
000144571 3367_ $$2BibTeX$$aARTICLE
000144571 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144571 3367_ $$00$$2EndNote$$aJournal Article
000144571 500__ $$a 2020 Jan;61(1):27-36
000144571 520__ $$aIt is a matter of debate whether myeloma patients with progressive disease (PD) after induction should receive salvage therapy or proceed directly to autologous stem cell transplantation. We performed a retrospective analysis of 1599 patients treated between 1991 and 2016 at the University Hospital of Heidelberg and other centers. Deepening of response through salvage therapy did not lead to better progression-free or overall survival (PD versus salvage therapy patients: HR = 0.71, 95% CI [0.28, 1.80], p = 0.5 and HR = 0.77, 95% CI [0.30, 1.95], p = 0.6, respectively), neither in patients treated with novel agents (HR = 0.66, 95% CI [0.23, 1.85], p = 0.4 and HR = 0.76, 95% CI [0.27, 2.15], p = 0.6) nor older regimens (HR = 0.86, 95% CI [0.36, 2.07], p = 0.7 and HR = 0.8, 95% CI [0.34, 1.91], p = 0.6). Therefore, primary nonresponders might benefit from a direct transplant rather than salvage induction, although the analyzed salvage therapy cohort was small (n = 23) and cytogenetics was not included in the multivariable analysis.
000144571 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000144571 588__ $$aDataset connected to CrossRef, PubMed,
000144571 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b1$$udkfz
000144571 7001_ $$aMueller-Tidow, Carsten$$b2
000144571 7001_ $$aGoldschmidt, Hartmut$$b3
000144571 7001_ $$aHillengass, Jens$$b4
000144571 773__ $$0PERI:(DE-600)2030637-4$$a10.1080/10428194.2019.1646905$$gp. 1 - 10$$n1$$p27-36$$tLeukemia and lymphoma$$v61$$x1029-2403$$y2020
000144571 909CO $$ooai:inrepo02.dkfz.de:144571$$pVDB
000144571 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000144571 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000144571 9141_ $$y2020
000144571 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000144571 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144571 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144571 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144571 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLEUKEMIA LYMPHOMA : 2017
000144571 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000144571 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000144571 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144571 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144571 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144571 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000144571 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000144571 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000144571 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000144571 980__ $$ajournal
000144571 980__ $$aVDB
000144571 980__ $$aI:(DE-He78)C060-20160331
000144571 980__ $$aUNRESTRICTED